COVID-19 Project Team: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Jose Loyola (talk | contribs) |
||
| (15 intermediate revisions by one other user not shown) | |||
| Line 8: | Line 8: | ||
=== {{AE}} === | === {{AE}} === | ||
* The name of the leaders are written in '''bold''': | |||
{{Multicol}} | {{Multicol}} | ||
'''First Draft of the page''' | |||
''' | *'''[[User:Syed Hassan Abbas Kazmi|Syed Hassan Abbas Kazmi, M.D.]]''' | ||
[[User:Aisha Adigun|Aisha Adigun, M.D]] | *'''[[User:Sabawoon Mirwais|Sabawoon Mirwais, M.B.B.S, M.D.]]''' | ||
'''Constant Update of the Page''' | |||
*[[User:Aisha Adigun|Aisha Adigun, M.D.]] | |||
'''Cardiovascular Disorders of COVID-19 Team Members''' | '''Cardiovascular Disorders of COVID-19 Team Members''' | ||
*[[User:Behjat|Alieh Bahjat, M.D.]] | *[[User:Behjat|Alieh Bahjat, M.D.]] | ||
| Line 21: | Line 24: | ||
*[[User:Sara Zand|Sara Zand, M.D.]] | *[[User:Sara Zand|Sara Zand, M.D.]] | ||
*[[User:Syed rizvi|Syed Rizvi, M.B.B.S.]] | *[[User:Syed rizvi|Syed Rizvi, M.B.B.S.]] | ||
*[[ | *[[User:TayyabaAli|Tayyaba Ali, M.D.]] | ||
'''Dermatologic Disorders of COVID-19 Team Members''' | '''Dermatologic Disorders of COVID-19 Team Members''' | ||
*'''[[User:Aditya Ganti|Aditya Ganti, M.B.B.S.]]''' | *'''[[User:Aditya Ganti|Aditya Ganti, M.B.B.S.]]''' | ||
*[[user:Dr.Nuha|Nuha AL-Howthi, MD]] | *[[user:Dr.Nuha|Nuha AL-Howthi, MD]] | ||
*[[User:Nnabude|Ogechukwu Hannah Nnabude, MD]] | *[[User:Nnabude|Ogechukwu Hannah Nnabude, MD]] | ||
'''Endocrinology and COVID-19''' | |||
*'''[[User:Tayyaba Ali|Tayyaba Ali, M.D.]]''' | |||
* [[User:Anahita|Anahita Deilamsalehi, M.D.]] | |||
{{ColBreak}} | |||
'''Frequently Asked Inpatient Questions Team Members''' | '''Frequently Asked Inpatient Questions Team Members''' | ||
* '''[[User:Gurman4sandhu|Gurmandeep Singh Sandhu, M.B.B.S.]]''' | * '''[[User:Gurman4sandhu|Gurmandeep Singh Sandhu, M.B.B.S.]]''' | ||
| Line 37: | Line 42: | ||
* [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]] | * [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]] | ||
* [[Ogechukwu Hannah Nnabude, MD]] | * [[Ogechukwu Hannah Nnabude, MD]] | ||
'''Frequently Asked Outpatient Questions Team Members''' | '''Frequently Asked Outpatient Questions Team Members''' | ||
* '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]''' | * '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]''' | ||
| Line 47: | Line 51: | ||
'''Gastrointestinal disorders and COVID-19''' | '''Gastrointestinal disorders and COVID-19''' | ||
*'''[[User:Farima Kahe|Farima Kahe, M.D.]]''' | *'''[[User:Farima Kahe|Farima Kahe, M.D.]]''' | ||
*[[ | *[[User:Javaria Anwer|Javaria Anwer, M.B.B.S.]] | ||
*[[User:TayyabaAli|Tayyaba Ali, M.D.]] | |||
* [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]] | * [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]] | ||
{{ColBreak}} | |||
'''Hematologic disorders of COVID-19 Team Members''' | '''Hematologic disorders of COVID-19 Team Members''' | ||
*'''[[User:Ramyar Ghandriz|Ramyar Ghandriz, M.D.]]''' | *'''[[User:Ramyar Ghandriz|Ramyar Ghandriz, M.D.]]''' | ||
| Line 61: | Line 66: | ||
*[[User:NNikravangolsefid|Nasrin Nikravangolsefid, M.D, MPH]] | *[[User:NNikravangolsefid|Nasrin Nikravangolsefid, M.D, MPH]] | ||
*[[User:MydahSajid|Mydah Sajid, M.D.]] | *[[User:MydahSajid|Mydah Sajid, M.D.]] | ||
'''Neurologic Disorders and COVID-19 Team Members''' | '''Neurologic Disorders and COVID-19 Team Members''' | ||
*'''[[User:Fahimeh Shojaei |Fahimeh Alsadat Shojaei, M.D.]]''' | *'''[[User:Fahimeh Shojaei |Fahimeh Alsadat Shojaei, M.D.]]''' | ||
*'''[[User:Syed Musadiq Ali|Syed Musadiq Ali, M.D.]]''' | *'''[[User:Syed Musadiq Ali|Syed Musadiq Ali, M.D.]]''' | ||
*'''[[User:Niloofarsadaat Eshaghhosseiny|Niloofarsadaat Eshagh Hosseiny, M.D.]]''' | *'''[[User:Niloofarsadaat Eshaghhosseiny|Niloofarsadaat Eshagh Hosseiny, M.D.]]''' | ||
*[[User:MoisesRomo|Moises Romo, M.D.]] | |||
*[[User:Muhammad Haider|Muhammad Adnan Haider, M.B.B.S.]] | *[[User:Muhammad Haider|Muhammad Adnan Haider, M.B.B.S.]] | ||
*[[User:Agnesrinky|Rinky Agnes Botleroo, M.B.B.S.]] | *[[User:Agnesrinky|Rinky Agnes Botleroo, M.B.B.S.]] | ||
*[[User:Parul Pahal|Parul Pahal, M.B.B.S.]] | *[[User:Parul Pahal|Parul Pahal, M.B.B.S.]] | ||
*[[User:Javaria Anwer|Javaria Anwer, M.B.B.S.]] | |||
{{ColBreak}} | |||
'''Ongoing Clinical Trials of COVID-19 Team Members''' | '''Ongoing Clinical Trials of COVID-19 Team Members''' | ||
* '''[[User:Hudakarman|Huda A. Karman M.D., M.P.H., M.S.]]''' | * '''[[User:Hudakarman|Huda A. Karman M.D., M.P.H., M.S.]]''' | ||
| Line 74: | Line 81: | ||
*'''[[Abdelrahman Ibrahim Abushouk|Abdelrahman Ibrahim Abushouk, M.D.]]''' | *'''[[Abdelrahman Ibrahim Abushouk|Abdelrahman Ibrahim Abushouk, M.D.]]''' | ||
* [[User:Harmeetkharoud91|Harmeet Kharoud, M.D,. MPH]] | * [[User:Harmeetkharoud91|Harmeet Kharoud, M.D,. MPH]] | ||
* [[User:Jose Loyola|José Eduardo Riceto Loyola Junior, M.D.]] | |||
* [[User:Sahar Memar Montazerin|Sahar Memar Montazerin, M.D]] | |||
'''Pulmonary Disorders and COVID-19 Team Members''' | '''Pulmonary Disorders and COVID-19 Team Members''' | ||
*'''[[User:Sara Mohsin|Sara Mohsin, M.B.B.S.]]''' | *'''[[User:Sara Mohsin|Sara Mohsin, M.B.B.S.]]''' | ||
| Line 80: | Line 89: | ||
*[[User:Rina Ghorpade|Rina Ghorpade, M.B.B.S.]] | *[[User:Rina Ghorpade|Rina Ghorpade, M.B.B.S.]] | ||
*[[User:Rija Gul|Rija Gul, M.B.B.S]] | *[[User:Rija Gul|Rija Gul, M.B.B.S]] | ||
'''Infectious Diseases and COVID-19''' | |||
''' | * [[User:Zaida Obeidat|Zaida Obeidat, M.D.]] | ||
*'''[[User: | * [[User:Syed rizvi|Syed Rizvi, M.B.B.S.]] | ||
''' | '''[[COVID-19 Medical Therapy]] | ||
* | * [[User:Sara Zand|Sara Zand, M.D.]] | ||
'''[[COVID-19 Other Diagnostic Studies]] | |||
* [[User:Mandana Safakhah|Mandana Safakhah, M.D.]] | |||
'''[[COVID-19 Vaccines]]''' | |||
* [[User:Jose Loyola|José Eduardo Riceto Loyola Junior, M.D.]] | |||
Latest revision as of 01:27, 24 August 2021
| COVID-19 Project |
|---|
| Introduction |
| Team |
| Meetings' Summary |
| Topics |
| Ongoing Clinical Trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]
Meet The Team
Associate Editor(s)-in-Chief:
- The name of the leaders are written in bold: